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Abstract
The c-Jun N-terminal kinase (JNK)-inhibiting peptide D-JNKI-1, syn. XG-102 was tested for its therapeutic potential in acute
inflammatory bowel disease (IBD) in mice. Rectal instillation of the chemical irritant trinitrobenzene sulfonic acid (TNBS)
provoked a dramatic acute inflammation in the colon of 7–9 weeks old mice. Coincident subcutaneous application of
100 mg/kg XG-102 significantly reduced the loss of body weight, rectal bleeding and diarrhoea. After 72 h, the end of the
study, the colon was removed and immuno-histochemically analysed. XG-102 significantly reduced (i) pathological changes
such as ulceration or crypt deformation, (ii) immune cell pathology such as infiltration and presence of CD3- and CD68-
positive cells, (iii) the production of tumor necrosis factor (TNF)-a in colon tissue cultures from TNBS-treated mice, (iv)
expression of Bim, Bax, FasL, p53, and activation of caspase 3, (v) complexation of JNK2 and Bim, and (vi) expression and
activation of the JNK substrate and transcription factor c-Jun. A single application of subcutaneous XG-102 was at least as
effective or even better depending on the outcome parameter as the daily oral application of sulfasalazine used for
treatment of IBD. The successful and substantial reduction of the severe, TNBS-evoked intestinal damages and clinical
symptoms render the JNK-inhibiting peptide XG-102 a powerful therapeutic principle of IBD.
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Introduction
Modulators of immune cells or immune responses belong to the
most intensively studied and most promising drugs. This holds also
true for the common diseases with inflammatory and/or auto-
immune pathologies such as rheumatoid arthritis, asthma, multiple
sclerosis, cancer or inflammatory bowel disease (IBD). The
pathogenetic development of IBDischaracterizedbythree causative
areas such as (i) genetic susceptibility for mutations of proteins
facilitating the access of microbes to the epithelium and underlying
layers, (ii) luminal antigenic provocation from endogenous microbes
or food allergens and (iii) environmental triggers (reviewed by
[1,2,3,4,5,6]). Many of these changes or risk factors are linked to the
signalling pathways regulating both the innate and adaptive immune
system. As a consequence, experimental strategies and present-day
medical therapies aim at the control of immune reactions and T cell
responses e.g. by aminosalicylates, corticosteroids, immunosuppres-
sants and immunomodulators including TNF-a-blockers [7,8].
The JNK, a group of mitogen-activated protein kinases (MAPK)
family members, are crucial mediators of various pathological
signalling pathways underlying IBD. JNK activity, which is
increased in IBD patients [9,10,11,12], sensitizes epithelial cells
against bacterial components and cytokines [13,14]. Among
numerous pathological alterations, JNKs are also involved in the
maturation and function of T cells, the production of cytokines
and the TNF-a-induced expression of E-selectin on endothelial
cells, which is critical for leukocyte adhesion and infiltration.
Moreover, JNK act as transducers of endoplasmatic reticulum
(ER) stress [3,9,11,15,16,17,18,19]. Therefore, inhibition of JNKs
emerges as a promising therapeutic principle in various inflam-
matory diseases including IBD [3,20,21,22] and was previously
shown to counteract colorectal tumorigenesis [23,24] that occurs
in the cause of chronic IBD.
So far, the development of anti-JNK therapies was limited due
to the lack of appropriate inhibitors with high specificity and cell-
permeability. The TAT-fused JNK-inhibiting peptide XG-102 (D-
JNKI-1) meets both criteria and is a substantial advancement [25].
As demonstrated in several preclinical studies, XG-102 and similar
peptidergic JNK-inhibitor could improve the outcome in several
degenerative processes like hearing loss [26], cerebral ischemia
[27], haemorrhage [28], retinal neovascularisation and retinal
exitotoxicity [29], metabolic syndromes including diabetes [30,31],
as well as atherosclerosis [32] (reviewed by [33,34,35]). In clinical
studies, XG-102 demonstrated therapeutic effectiveness in trau-
matic hearing loss [36] and uveitis [37].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e30985In the present study, we investigated for the first time the
therapeutic potential of the JNK-inhibiting peptide XG-102 to
counteract the pathological features provoked by TNBS, an acute
model of IBD with predominant T helper 1 (Th1)-mediated
immune response [38,39].
The single subcutaneous application of 100 mg/kg XG-102
powerfully reduced the pronounced clinical, histological and
immunological alterations and lesions following acute TNBS
colitis in mice. The therapeutic effectiveness of a single XG-102
application was at least as potent as the repetitively applied
standard competitor and clinical drug sulfasalazine.
Results
Disease activity index (DAI)
Normal mice. Normal mice gained per average 1.7% on
average of their body weight within 72 h , the hemoccult of all
normal mice was negative and DAI did not surpass 1.3 (Fig. 1).
TNBS. After TNBS instillation, weight loss started rapidly.
Within 24 h, animals lost 10.5% per average of their body weight
and after 72 h, the end of the observation period, weight loss was
still 9.3% compared to the body weight before the TNBS
administration. TNBS provoked severe diarrhoea with blood. The
initial hemoccult score was 2.5 on average after 24 h and declined
to 1.1 after 72 h. The DAI reflected these changes with a maximum
of 7.8 after 24 h, and it was still elevated with 5.1 after 72 h (Fig. 1).
Subcutanous XG-102. The sc. injection of XG-102
significantly and dose-dependently attenuated the clinical
parameters. One hundred mg/kg XG-102 sc. most effectively
reduced weight loss and the animals almost completely regained
their initial body weight. Moreover, the hemoccult score was
significantly (p,0.05, data not shown) attenuated after 24 h and
was almost normal after 72 h. In consequence, XG-102 dose-
dependently diminished the composed DAI by more than 50%
(p,0.01) at 100 mg/kg after 24 and 48 h (p,0.05) (Fig. 1). For sc.
application of 50 mg/kg XG-102 scores were all consistently better
compared to solvent treatment, but did not reach significance.
10 mg/kg sc. XG-102 was not effective (data no shown).
Oral sulfasalazine. Daily 10 mg/kg sulfasalazine was as
effective for the reductions of weight loss and DAI as single sc.
100 mg/kg XG-102 (Fig. 1).
Gross pathology and histological analysis (H&E stain)
Macroscopical inspection of the colon immediately after the
animals’ death, showed a strong hyperemia, necrosis, and
inflammation after TNBS administration. It was obvious that
100 sc. XG-102 or 10 mg/kg po. sulfasalazine attenuated these
features.
Tissue damage
Normal mice. Healthy mice displayed regular crypts with
goblet cells; lymphocytes in the lamina propria were rarely
detectable. Occasional lymphoid nodules were identified in the
submucosa. Inflammatory infiltrates were absent. Normal crypts
were linked with the underlying lamina muscularis.
TNBS. The TNBS administration caused a severe transmural
inflammation characterized by infiltration of inflammatory cell
(Fig. 2). The inflammation was accompanied by multifocal
dropouts of entire crypts and severe ulcerations, loss of goblet
cells, and fibrosis. As a further characteristic change of the acute
inflammation, the submucosa was enlarged by a pronounced
oedema. The maximum of pathological alterations was found in
the distal part of the colon, but was also present in the medial part
(Fig. 2).
XG-102. Subcutaneous application of 100 mg/kg XG-102
significantly reduced the parameters of inflammation and tissue
destruction. The total score of the three histological parameters
was significantly attenuated by sc. XG-102 equally in the distal
colon (p,0.01) and medial colon (p,0.001) (Fig. 2). XG-102
almost completely restored the histological appearance of the
mucosa compared with the TNBS group.
Sulfasalazine. Sulfasalazine reduced the H&E parameters in
the distal and medial colon (Fig. 2), but did not reach significance.
Infiltration of immune cells
Besides the severe tissue damage, TNBS caused a massive
infiltration of immune cells in the distal colon and to a lesser extent
in the medial part. The infiltration comprised the invasion of
macrophages, lymphocytes and leukocytes (Fig. 2).
Only 100 mg/kg XG-102 sc. significantly (p,0.01) lowered the
infiltration score in both the distal and medial colon. The decrease
following sulfasalazine did not reach significance (Fig. 2).
CD3 and CD68 Immunofluorescence
Normal mice and TNBS. In normal animals, only few CD3-
and CD68-positive cells were detectable (Fig. 3, 4). TNBS evoked
a dramatic infiltration of CD3- and CD68-positive cells in the
lamina propria, submucosa and epithelium (Fig. 3, 4).
XG-102. Single subcutaneous application of 100 mg/kg XG-
102 significantly (p,0.05) diminished the numbers of CD3- and
Figure 1. Time course of disease activity index. Time course of disease activity index (DAI) (mean+SEM) in normal mice (normal, n=5),
following rectal administration of trinitrobenzene sulfonic acid (TNBS) only (TNBS, n=27) or treatment with XG-102 (100 mg/kg sc., n=16) or
sulfasalazine (10 mg/kg, po. daily, n=12). *, **, ***=p,0.05, p,0.01 and p,0.001 for all groups compared with TNBS group.
doi:10.1371/journal.pone.0030985.g001
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signals were attenuated in all layers of the distal colon, i.e.
epithelium, lamina propria and submucosa (Fig. 4). In the medial
colon, the reduction of CD3-positive cells reached almost
significance.
Production of TNF-a
TNF-a release was measured in organic colon cultures 24 h
after the removal of the colon. TNBS provoked a dramatic rise in
TNF-a concentration to 261647 pg/ml compared to normal
mice (67620 pg/ml). Treatment with XG-102 (100 mg/kg sc.)
significantly (p,0.01) reduced the TNF-a production (8966 pg/
ml) to concentration levels of normal mice (Fig. 5).
Markers of Apoptosis
Inflammation in the gut causes apoptotic cell death in intestinal
mucosa [5,7,40]. To investigate the potential of XG-102 to
attenuate TNBS-induced apoptosis, Western blot analysis of
apoptotic proteins were performed with lysates from colon tissue
12 h, 24 h and 72 h after TNBS application. The levels of cleaved
i.e. activated caspase-3 activity were substantially enhanced after
24 h compared to normal mice (Fig. 6A). XG-102 (100 mg/kg sc.)
almost completely abrogated the signal of caspase-3 activity,
whereas the presence of total uncleaved caspase-3 remained
unchanged (Fig. 6A). Immunoreactivity of cleaved caspase-3 was
localized in the deranged epithelium (data not shown). Protein
expression of Bax and Bim, regulators of programmed cell death,
were increased with maximal levels after 12 h and 24 h,
respectively (Fig. 6B). XG-102 lowered these expressions at all
time points investigated (Fig. 6B). Similarly, XG-102 attenuated
the expression levels of FasL and p 53 (Fig. 6C).
The activation of Bim depends on its physical interaction with
JNK [41] but this issue has not been addressed so far in intestinal
tissues. Here we provide evidence that both, JNK1 and JNK2 can
be seen in Bim positive protein complexes, but it is JNK2 only that
is increased in this protein pool from whole cell lysates (Fig. 7).
XG-102 does not only prevent this up regulation but almost
completely abolishes the Bim-JNK2 signal.
Summarizing these data that JNK are strong inducers of TNBS-
induced apoptosis. The JNK inhibitor XG-102 substantially
reduces various apoptotic features.
Expression and activation of c-Jun
Finally, the expression of c-Jun and its N-terminal phosphor-
ylation exclusively catalyzed by JNKs, were determined either in
whole cell extracts by Western blotting (Fig. 8) or immunohisto-
chemistry.
Expression of c-Jun was maximal until 12 h and declined to
control levels after 24 h (Fig. 8). Phosphorylation of c-Jun revealed
a similar time course. Single application of XG-102 (100 mg/kg
sc.) attenuated both the expression and activation of c-Jun (Fig. 8),
and this attenuation can be considered as indirect proof of
inhibition of JNK by XG-102. Activation of JNK reached its
maximum after 3 h and strongly decreased after 12 h; these
changes were not affected by XG-102 (data not shown).
In the colon of normal mice, only a restricted number of
scattered cells were immunoreactive for c-Jun and immunoreac-
tive phospho-c-Jun was absent. Between 3 h and 12 h after TNBS,
the expression of c-Jun increased in the crypts, intestinal wall and
infiltrating immune cells, confirming the results from Western
blotting (data not shown). The nuclear immunoreactivity of
phosphorylated c-Jun was predominantly localized in the damaged
epithelium. The intensity of phospho-c-Jun immunoreactivity in
infiltrated inflammatory cells correlated with the extent of
inflammation. These p-c-Jun signals were substantially attenuated
within 12 h following XG-102 (100 mg/kg sc.) (immunohisto-
chemical data not shown).
Thus, the JNK signalling pathway is rapidly activated during
early IBD development following local TNBS and reduced by the
JNK inhibitor peptide XG-102.
Discussion
The present study has addressed for the first time the effect
of the peptidergic and highly specific JNK inhibitor XG-102
on TNBS- induced acute colon inflammation, a disease model
which shares pathophysiological properties of Crohn’s disease
[38,39,42,43].
The basic and strong pro-inflammatory actions of JNKs and the
potent anti-inflammatory effects of JNK-inhibitors [33] raised the
question of the protection of inflamed colon tissue by XG-102.
Results indicate that the JNK inhibitor XG-102 protects against
characteristic pathological features of TNBS-triggered colon
inflammation. The effect of a single application of XG-102 was
at least as pronounced or even better as the daily oral gavage of
sulfasalazine, a standard drug for experimental and of clinical
treatment inflammatory bowel diseases (IBD) [7,8].
Dose-dependently, XG-102 significantly reduced the clinical
parameters (body weight, blood in stool, stool consistency),
ulceration, crypt deformations, immune cell infiltration, produc-
Figure 2. Hematoxylin and eosin (H&E) scores. Hematoxylin and
eosin (H&E) scores from distal (A) and medial (B) colon. For the tissue
damage score (hatched bars), the scores of ulcer, crypts and submucosa
were summed-up for each individual animal, and the mean6SEM was
calculated for each group. The mean6SEM of the infiltration score (grey
bar) is separately shown. ***, **=p,0.001 and p,0.01 for all groups
compared with TNBS group.
doi:10.1371/journal.pone.0030985.g002
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and p53, the complexation of JNK2 with Bim and finally,
expression and activation of c-Jun.
Normalization of clinical features
A single TNBS instillation induces transient clinical changes
(summarized by the disease activity score index, DAI) which
return to normal pre-experimental values between 4 and 7 days. In
order to detect the protective effects by XG-102, we terminated
the experiments after 72 h, i.e. before normalization of DAI
components.
In our hands, maximal weight loss reached 14% on average
after TNBS, an extent similar to other reports [44,45]. The action
of XG-102 was rather fast, since it significantly attenuated JNK
Figure 4. Representative CD3 and CD68 immunofluorescence. Representative CD3 (left) and CD68 (right) immunofluorescence of the distal
colon from normal mice, trinitrobenzene sulfonic acid (TNBS) administration and treatment with sc. 100 mg/kg XG-102.
doi:10.1371/journal.pone.0030985.g004
Figure 3. Infiltration and presence of CD3- and CD68-positive cells. The proportion (%) of CD3- or CD68-positive cells from all cells within a
defined vision field in the distal and medial colon from normal mice (normal, n=5), following rectal trinitrobenzene sulfonic acid (TNBS)
administration only (TNBS, n=6) and treatment with XG-102 (100 mg/kg sc.) (n=7). *, **=p,0.05 and p,0.01 compared with TNBS group.
doi:10.1371/journal.pone.0030985.g003
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confers a long-lasting action at least for 72 h, when the clinical
parameters of DAI had returned to pre-experimental values. The
re-gain of body weight could be merely due to an improved
drinking response, but the normalization of hemoccult and stool
consistency indicates a true limitation of the inflammatory process.
Morphological alterations
The pathogenetic mechanism of TNBS-induced colitis, a
delayed-type hypersensitivity response to the hapten-modified self
antigens [43,46], comprises the destruction of epithelial cells and
infiltration of lymphocytes, which in turn stimulates a regional
inflammation through production of cytokines and other inflam-
matory mediators [19].
The histological examination of the colon from TNBS-treated
mice showed a dramatic inflammation with parameters of immune
cell infiltration and ulcerative tissue destruction after 72 h. The
JNK inhibitor XG-102 most effectively reduced this pathological
histopathology and almost normalized the colon tissue. This is in
line with recent studies using different inhibitors of the JNK
pathway such as SB203580 or SP600125 [9,11,46] or molecules
interacting with MAPK like curcumin [47]. For the most part,
these inhibitors have been tested in studies of either dextran
sulphate sodium–induced (DSS) colitis or hapten-induced colitis
(TNBS) in mice or rats, to study their capacities to prevent
mucosal inflammation rather than their capacities to reverse
established inflammation, a more stringent test.
Inflammation and immune cell infiltration
XG-102 counteracted the infiltration of immune cells as shown
for CD 3- and CD68-positive cells. CD3 is an antigen and part of
the T cell receptor (TCR) complex on mature T lymphocytes, and
CD68 marks macrophages. This is perfect in line with data from
human specimen from IBD patients [20]. The immuno-modulat-
ing actions by inhibition of JNK is a common finding in various
models of experimental inflammation e.g. animal models for
arthritis, pulmonary inflammation, atherosclerosis and other
immune challenging procedures (reviewed by [33,35]).
Figure 5. Production of TNF-a. TNF-a release (pg/ml) into the
supernatant of organic colon culture from normal mice, following
trinitrobenzene sulfonic acid (TNBS) only, and treatment with sc.
100 mg/kg XG-102. **=p,0.01 for all groups compared with TNBS
group.
doi:10.1371/journal.pone.0030985.g005
Figure 6. Apoptosis. Western blot analysis of (A) caspase-3 and
cleaved caspase-3, (B) Bax and Bim, and (C) FasL and p53 from colon
extracts of untreated controls (co) 12 h, 24 h and 72 h following
trinitrobenzene sulfonic acid (TNBS) administration without or with XG-
102 (100 mg/kg sc.). These blots are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0030985.g006
Figure 7. JNK2-Bim co-precipitation. JNK1 and JNK2 immunopre-
cipitates (IP) from colon tissue homogenates were analyzed by Western
blotting with an anti-Bim antibody. Pounceau staining demonstrated
equal loading (data not shown).
doi:10.1371/journal.pone.0030985.g007
Figure 8. c-Jun and phospho-c-Jun. Western blot analysis of c-Jun
and phospho-c-Jun in colon homogenates from untreated controls (co)
and 12 h or 24 h following trinitrobenzene sulfonic acid (TNBS)
administration without or with XG-102 (100 mg/kg sc.). These blots
are representative of 3 independent experiments.
doi:10.1371/journal.pone.0030985.g008
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Activation of caspase-3 is the central event of the major type of
cellular apoptosis, and in many cases, it occurs downstream of
JNK activation (reviewed by [48]). The almost complete
disappearance of cleaved, i.e. activated caspase-3 following XG-
102 might be consequence of attenuated Bax or Bim expression as
well as the decrease of JNK2:Bim-complex. JNK2, but not JNK1,
was found as the JNK isoform responsible for osmotic stress [49].
Features of apoptosis have been regularly described following IBD
pathologies including TNBS [39]. The same is true for the
production and/or release of TNF-a and the expression of its
receptors [11]. Very recently, lamina propria macrophages were
identified as a source of TNF-a [50]. Together with other
cytokines, TNF-a holds a central position within immune cell
activation and tissue destruction, and the application of TNF-a-
antibodies and other antagonistic molecules [51] is a novel
therapeutic strategy in the treatment of colitis ulcerosa and/or
Crohn’s disease (reviewed by [7]). However, TNF-a antibody
therapy keeps not more than 50% in remission after one year
[52,53,54].
XG-102 normalizes the enhanced production of TNF-a in
colon tissue cultures. JNKs are important mediators of TNF-a
signaling [55].
Mechanisms of XG-102 actions
IBD pathologies rapidly enhance the activation of JNK and its
transcriptional effector substrate c-Jun in animals and humans,
and link the JNK pathway with the initiation and development of
intestinal or gastric inflammation including human IBD
[9,11,12,40,56]. Moreover, a correlation has been proposed
between the site of JNK activity and loss of responsiveness to
steroids [57].
XG-102 blocks the catalytic action of JNK, but not its
activation, by inhibition of JNK scaffold formation [27,58].
Therefore, the analysis of phosphorylated JNK is inappropriate
to visualize the functional level of XG-102. Moreover, antagonisa-
tion of JNK activity including inhibitors of the ATP-binding site
such as SP600125 increase the level of phosphorylated JNK and
their upstream kinases [59] most likely by failure of negative feed
back.
The rapid and effective inhibition of JNK by XG-102, i.e.
simultaneous but not pre-emptive application with the TNBS
provocation, might explain the effectiveness of XG-102. In
previous studies with experimental colitis or specimen from
patients, inhibition of JNK was followed by down-regulation of
c-Jun phosphorylation [9] and AP-1 target genes such as cyclo-
oxygenases, MCP-1, ICAM-1 or release of cytokines [9,20]
(reviewed by [21]. Attenuation of activated AP-1 transcription
factor c-Jun was seen in experimentally of TNBS and DSS colitis
[40,57]. In our hands, XG-102 attenuates the expression of c-Jun
and to a similar extent its N-terminal phosphorylation which is
exclusively catalyzed by JNKs.
The recent claim that JNK are not part of the IBD pathology
merely derives from a missing rise in JNK expression [60].
Previous observations have already reported on persistent JNK
expression with strong rise of its phosphorylation i.e. after cerebral
ischemia [61]. JNK are mainly regulated by post-translational
modifications and more importantly, by stimulus-specific distribu-
tion of JNK isoform within various cellular compartments
[61,62,63].
The mechanisms of XG-102 are not yet fully understood.
Beyond inhibition of JNK functions, it seems to interfere with
further pathological processes such as autophagy [64]. The
principle of JNK inhibition by peptidergic block of the interaction
domain offers the putative advantage to target only JNK
signalosoms formed under pathological conditions (discussed
[65]. The variation of the length of TAT-sequence and D/L-
stereometry enables efficient variations of half life. Moreover, the
exclusive specificity of JNK is in striking contrast with the
pronounced inhibition of many other kinases by inhibitors of
the ATP-domain [66].
The putative use of XG-102 for clinical therapy is tested in
clinical studies e.g. of traumatic hearing loss [67] and uveitis ([37])
at present. In pre-clinical animal experiments, XG-102 and a
similar peptidergic JNK-inhibitor conferred promising beneficial
effects in models for cerebral ischemia ([27,68,69]), diabetes
([30,70]), atherosclerosis ([32]) or lung inflammation (reviewed by
[33,35,71]).
Conclusion and outlook
ThesingleapplicationoftheJNKinhibitorypeptideXG-102(syn.
D-JNK1-I) confers a rapid and lasting anti-inflammatory effective-
ness in experimental colitis provoked by the strong immunotoxin
TNBS. The therapeutic effect does not require a pre-emptive
applicationnoranylatencytime.TheeffectsofXG-102coverawide
rangeofimmunopathologicalfeaturessuchasnormalizationoftissue
destruction, loss of body weight and hemorrhage, cytokine
production, apoptosis or immune cell invasion.
XG-102 does not directly interfere with the newly identified
pathogenic molecules such as NOD2, ATG16L1 or Th17-
lymphocytes [5]. Since IBD pathologies are complex multifactorial
processes, XG-102 offers the advantage to block a central
converging point for several immunopathological signal cascades.
Materials and Methods
Ethics Statement
Female BALB/c mice, 7 to 10 weeks old with 16–23 g body
weight (Charles River Laboratories, Sulzfeld, Germany), were kept
in polycarbonate cages in temperature-controlled rooms with 12 h
light/dark cycle and access ad libitum to water and standard
rodent food before and during the study. The mice were
randomized into groups up to 8 animals. Clinical investigations
and all immuno-histological scorings were performed in a double
blinded fashion. This study was carried out in strict accordance
with the approval of the Ministerium fuer Landwirtschaft und
Naturschutz of Schleswig-Holstein (V 312-72241.121-22, 60-6/08
and 74-6/09) and was in agreement with the guidelines for the
proper use of animals in biomedical research.
Induction of colitis by TNBS
Th 1-mediated colitis was induced via rectal instillation of the
haptenating agent TNBS (2,4,6-TNBS; Sigma-Aldrich, Munich,
Germany). 2 mg TNBS were dissolved in 47.5% ethanol and
applied in a final volume of 150 ml per animal. A 3.5-F-catheter
was carefully inserted approximately 4 cm into the rectum under
short anaesthesia of CO2. Mice were carefully held in a vertical
position for 1 min after the TNBS administration to ensure
distribution of TNBS within the colon and caecum. At the end of
all experiments, i.e. between 3 and 72 h after TNBS instillation,
the mice were killed by CO2 overdose.
Administration of the test compounds
XG-102 (also termed D-JNKI-1) was synthesized and delivered
by Xigen Pharm. (Epalinges, Swiss). XG-102 was dissolved in
0.9% NaCl solution for subcutaneous (sc.) application. XG-102
was tested as 10, 50 and 100 mg/kg for sc. application. XG-102
was given as single dose immediately before TNBS administration.
JNK Inhibition Protects against Colitis
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before rectal TNBS administration.
As positive control, 10 mg/kg sulfasalazine (Sigma-Aldrich,
Munich, Germany) was daily applied per os (po) by gavage, the
first dose immediately before TNBS instillation. Normal animals
served as healthy controls.
Quantification of disease activity
Disease activity index (DAI) comprising body weight, stool
consistency and rectal bleeding was determined daily between 8
and 10 am as described in detail elsewhere [72]. The scores from
these three parameters were summed-up as DAI ranging from 0
(healthy) to 12 (maximal severity of colitis).
Macroscopical inspectation and histological analysis of
the colon (H&E stain)
After sacrifice, the colon was quickly removed, gently rinsed
with saline solution and the macroscopically visible damage of the
colon was assessed. The colon was cut in three parts and tissues
were fixed in 4% formalin, embedded in paraffin and cut into
0.5 mm thick sections. Sections were deparaffinized with xylene,
rehydrated through graded concentrations of ethanol and stained
with hematoxylin (Roth, Karlsruhe, Germany) and eosin (Merck,
Darmstadt, Germany) (H&E) using routine techniques. Four to six
colon rings from medial and distal colon segment were used for
histological examination. Again, histological scoring was per-
formed in a double-blinded manner by two investigators. H&E-
scores were determined for 100 mg/kg XG-102 sc. only, and not
for the other XG-102 concentrations.
The inflammation score was 1, presence of occasional inflamma-
tory cells in the lamina propria; 2, confluence of inflammatory cells
extending into the submucosa; 3, transmural extension of the
immune cell infiltration.
The tissue damage score (ranging from 0 to 9) was composed by the
three parameters thickness of submucosa, structure of crypts and
erosion/ulcer (each ranging 0–3). Table 1 gives the score details.
Immunofluorescence
7 mm cryosections were fixed in ice-cold acetone (5 min),
followed by sequential incubation with blocking solution (normal
goat serum, Vector, Burlingame, USA) to eliminate unspecific
background staining. Slides were incubated for 1 h at room
temperature (RT) with the primary antibody against CD3 (1:50;
rabbit; Abcam, Cambridge, USA) and CD68 (1:50; rat; Hycult
Biotechnology, Beutelsbach, Germany). After washing three times
with phosphate-buffered saline (PBS), slides were incubated for
45 min at RT with carbocyanine (Cy3)- or fluorescein isothiocy-
anate (FITC)-labelled secondary antibody (1:200; Jackson Im-
muno Research Lab., Suffolk, UK). Finally, nuclei were
counterstained with Finally, nuclei were counterstained with 49,
6-diamidino-2-phenylindole (Sigma-Aldrich, Munich, Germa-
ny).The total number of cells and CD3- or CD68-positive cells
were counted in four random sight fields (ROI 6006600 pixels)
comprising the mucosa and submucosa each from distal and
medial colon segment. The percentages of positive immune cells
from the total cell population per vision were calculated.
Fluorescence was detected by an Axiophot microscope
(LSM510; Zeiss, Jena, Germany) with appropriate filter systems.
Production of TNF-a
The production of TNF-a was investigated in every second
animal (total n=16). A 1-cm-segment of the transversal colon was
removed, cut open longitudinally, and washed in PBS (containing
penicillin and streptomycin). The fragment was placed, and
incubated in 24 flat-bottom well culture plates containing 1 ml of
fresh RPMI 1640 medium (PAA, Co ¨lbe, Germany; supplemented
with penicillin and streptomycin) at 37uC for 24 h. TNF-a was
quantified using commercially available enzyme-linked immuno-
sorbent assay (ELISA) kits (Cytoset kit; Bio-Source International,
Camarillo, USA) according to manufacturers’ protocols.
Preparation of soluble cell lysates
After sacrifice of the animals, the colon tissue was frozen
immediately in liquid nitrogen and stored at 280uC. Thereafter,
the tissue was homogenized in 0.2–0.4 ml of lysis buffer containing
50 mM Tris-HCl (pH 7.5), 8 mM MgCl2, 0.5 mM EDTA, 5 mM
EGTA, 250 mM NaCl, 0.01 mg/ml Pepstatin, 0.01 mg/ml
Leupeptin, 0.01 mg/ml aprotinin and 1 mM phenylmethylsul-
phonyl fluoride (Sigma Chemical, St. Louis, USA). The lysates
were frozen and thawed three times and incubated on ice for
30 min. After sonication for 10 s, the tissue samples were
centrifuged at 15,0006 g for 15 min at 4uC. Protein concentra-
tions were determined using Dye Reagent, a variant of Bradford’s
colorimetric assay (Roth, Karlsruhe, Germany).
Immunoprecipitation
For immunoprecipitation (IP) native cell lysates were prepared
from colon tissue. The tissue was homogenized in native lysis
buffer [(20 mM Tris (pH 7.6), 250 mM NaCl, 3 mM EDTA,
3 mM EGTA, 0.5% Non-diet, 1% phosphatase inhibitor (Sigma)
and 1% ß-glycerolphosphate and 1% protease inhibitor (Roche)],
incubated on ice for 30 min and centrifuged to remove insoluble
material (15,0006g for 15 min, 4uC). Supernatants were normal-
ized for total protein content and stored at 280uC. One hundred
fifty mg of total proteins were precleared, mixed with the
precipitation antibody (1 mg) for 6 h and incubated overnight
with 30 ml of 50% of protein-A Sepharose (Sigma). Immobilized
protein complexes were washed 3 times with lysis buffer and twice
with PBS. The immobilized proteins were dissociated with 56
reducing electrophoresis buffer in 20 ml of ultra-pure water at
95uC for 5 min. the supernatants from the dissociation were
carefully loaded onto 15% SDS-gel whereas the matrix was
removed by centrifugation.
Table 1. Tissue damage scores.
Score parameter
Submucosa 0 thickness 0 mm
1 ,15 mm
2 15–40 mm
3 .40 mm
Crypt structure 0 normal appearance
1 crypt length reduced by ,30%
2 crypt length reduced by ,30%+loss
of goblet cells
3 complete loss of crypts and epithelium
Erosion/ulceration 0 epithelium normal, intact
1 damage of lamina propria
2 damage of submucosa
3 transmural
ulceration
doi:10.1371/journal.pone.0030985.t001
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Conventional Western blot analysis was conducted as described
previously [62]. Primary antibodies against c-Jun (Santa Cruz,
Heidelberg, Germany) was diluted 1:1000, phospho-c-Jun (Cell
Signaling Tech., Danvers, USA) 1:1000, total JNK 1:1000,
phospho-JNK (Promega, Mannheim, Germany) 1:2000, caspase-
3 (Santa Cruz, Heidelberg, Germany) 1:1000, cleaved caspase-3
(Cell Signaling Tech., Danvers, USA) 1:1000, Bim 1:2000, Bax
1:1000, FasL 1:1000 (Santa Cruz, Heidelberg, Germany), p53
(Cell Signaling Tech., Danvers, USA) 1:1000 and against actin
(Sigma-Aldrich, Munich, Germany) diluted 1:5000.
Immunohistochemistry
Sections of 0.5 mm thickness were deparaffinized in xylene and
rehydrated through graded concentrations of ethanol. After
rehydration, the endogenous peroxidase was blocked with 2%
hydrogen peroxide followed by antigen retrieval by microwaving
sections in sodium citrate buffer (10 mM sodium citrate, 0.05%
Tween 20, pH 6.0). Following antigen retrieval, the sections were
washed with PBS; non-specific binding was blocked with 0.75%
bovine serum albumin for 20 min. The incubation with primary
antibodies proceeded at 4uC overnight. Antisera against c-Jun
(Santa Cruz, Heidelberg, Germany) were diluted 1:500, phospho-
c-Jun (Cell Signaling Tech., Danvers, USA) 1:250. After repeated
washings in PBS, sections were incubated with biotinylated
secondary antibody for 45 min followed with an avidin-biotin
complex (Vector Laboratories, Burlingame, USA) for 45 min.
Controls were processed without the primary antibody. Staining
was visualized by diaminobenzidine tetrahydrochloride (Sigma-
Aldrich, Munich, Germany) for 5–10 min at RT. The immuno-
hisochemical signals were taken and analysed by a digital camera
system (Leica QWin image analysis system, Wetzlar, Germany).
Statistical analysis
All results including graphics were expressed as the mean +
SEM. Statistical analysis was performed by ANOVA 1-way or
Kruskal-Wallis test as appropriate followed by Dunnett’s t-test or
Dunn’s test, respectively. The levels of significance *, **, *** were
defined as p,0.05, p,0.01 and p,0.001, respectively. The
effectiveness of XG-102 and sulfasalazine against TNBS provoked
alterations were tested in TNBS animals which received sc. saline.
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